Industry veteran appointed as Chief Scientific Officer of OxStem Ltd
Dr. Georg C. Terstappen has been appointed to the role of Chief Scientific Officer (CSO) of spinout OxStem Ltd.
Evox Therapeutics secures £35.5m Series B
The Oxford University spinout will use the investment to further develop its exosome technology, capable of delivering drugs to previously inaccessible parts of the body.
Celleron Therapeutics enrols patients for clinical trial
Celleron Therapeutics, spun out of the University in 2005, has commenced a Phase Ib/II clinical trial investigating drug combination therapy for colorectal cancer.
Digital health software for heart failure treatment exclusively licensed to Sensyne Health
Support-HF, developed by The George Institute for Global Health at the University of Oxford and Oxford University Hospitals NHS Foundation Trust, will support patients and clinicians in managing heart failure and curate data for medical research using Clinical AI.
Oxford University Innovation Q2 2018 Update
Oxford University spinout external investment nears £1.9bn since 2011 - £506m of which was in the past twelve months.
Oxford University senses spicy deal with Zimmer and Peacock
Oxford University Innovation licenses sensors for garlic, ginger and turmeric to Zimmer and Peacock.
Oxford University spinout lasers in on diamond security
Opsydia, an Oxford University spinout founded last year to create a new level of diamond and gemstone security, officially launches with De Beers deal.
Orbit Discovery raises £6.9m for peptide library
Oxford Sciences Innovation leads round into Orbit Discovery, an Oxford University spinout developing a peptide platform.
Enhanced test for Alzheimer’s risk from Cytox
Oxford University spinout Cytox has announced an extension of its test for assessing the genetic risk of developing Alzheimer's disease.
Body temperature liver storage technique improves transplant success
Preserving livers at body temperature has been shown to improve transplant success and to increase the number of viable donor livers available for transplant. The study, which used a normothermic perfusion device from spinout OrganOx, presages shorter waiting lists for patients and lower mortality rates.
